Skip to main content

Table 1 Endpoints from study investigating single agent celecoxib by Mantovani et al [21]

From: A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study

  Baseline After treatment pvalues
TNF-alpha (pg/ml) 36.8 ± 14.1 29.9 ± 12.2 0.007
LBM (Kg) 45.4 ± 6.7 45.8 ± 6.6 < 0.0001
QoL 66.3 ± 19.9 75.3 ± 10.1 0.024
ECOG PS 1.5 ± 0.67 1.2 ± 0.59 0.0023
GPS 1.3 ± 0.77 0.8 ± 0.7 0.0004
Grip strength 20. 8 ± 4.7 24.0 ± 5.5 0.004
  1. TNF-alpha = Tumour Necrosis Factor-alpha, LBM = Lean body mass, QoL = Quality of life, ECOG PS = Eastern Cooperative Oncology Group (ECOG) Performance status, GPS = Glasgow prognostic score. Data are reported as mean ± SD.